Merck Patent Gmbh

Other

Cancer Research Technology Limited

Marck Patent Gmbh

Lead Discovery Center Gmbh

Christina Esdar

Margarita Wucherer-Plietker

Dieter Dorsch

Lars Thore Burgdorf

Markus Klein

Christos Tsaklakidis

Paul Czodrowski

Oliver Schadt

Hans-Peter Buchstaller

Hartmut Greiner

Ulrich Emde

Mathilde Muzerelle

Timo Heinrich

Birgitta Leuthner

Dirk Finsinger

Ulrich Graedler

Hans Peter Buchstaller

Joerg Bomke

Kai Schiemann

Frank Stieber

Brian Lewis Hodous

Andree Blaukat

Christian Sirrenberg

Melanie Schultz

Bjoern Hock

Thomas J J Mueller

Eugen Merkul

Mireille Krier

Jan Eickhoff

Lars Toleikis

Carsten Schultz-Fademrecht

Christel Iffland

David Bruge

Oliver Poeschke

Qi An

Gang Hao

Michel Calderini

Vanita D Sood

Felix Rohdich

Xinyan Zhao

Johannes Yeh

David Nannemann

Robin Lytle

Margarita Wucherer-plietker

Thomas J Mueller

Margarita Wuchrer

Graedler Ulrich

Compounds of the formula I in which X, X, X, X, R, R, R, Q and Y have the meanings indicated in claimare inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Quinolin-2-one derivatives

α-Amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases, and cancer.

Boronic acid derivatives

The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

Monoclonal antibody directed to FGFR1

&#x3b1;-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.

Compounds of the formula I in which X, X, X, X, R, R, R, Q and Y have the meanings indicated in Claimare inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.

Compounds of the formula I in which R, X and n have the meanings indicated in Claim, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Phthalazine derivatives

The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

Azaheterocyclic compounds

The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-ethyl-1 -(pyrimidin-5-yl)-1H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,is an inhibitor of RON and can be employed, for the treatment of cancer.

Quinoline inhibitor of the macrophage stimulating 1 receptor MSTR1

Compounds of the formula I in which U, V and W have the meanings indicated in Claim, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors

Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.

Bicyclic heteroaromatic compounds

Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumors.

Pyrrolo [2,3&#x2014;D] pyrazin&#x2014;7&#x2014;ylpyrimidine compounds

Compounds of the formula (I), in which R, Rand Rhave the meanings indicated in Claim, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.

Pyrimidine derivatives as FAK inhibitors

A variety of specific compounds within the scope of formula I which are useful as PI3K inhibitors and can be employed for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours, and pharmaceutical compositions and kits containing said specific compounds.

Quinoxalines derivatives and pharmaceutical compositions and kits

Growing community of inventors

Mainz, Germany

Christina Esdar